Analysts Set Expectations for CRBU Q1 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for Caribou Biosciences in a research report issued to clients and investors on Monday, November 17th. HC Wainwright analyst R. Burns expects that the company will earn ($0.36) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.39) EPS and Q4 2026 earnings at ($0.41) EPS.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.06. Caribou Biosciences had a negative net margin of 1,690.45% and a negative return on equity of 69.85%. The business had revenue of $2.20 million during the quarter, compared to analyst estimates of $1.94 million.

A number of other analysts have also recently weighed in on CRBU. Citigroup increased their price target on Caribou Biosciences from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Caribou Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 24th. Finally, Truist Financial set a $7.00 price target on shares of Caribou Biosciences in a research report on Tuesday, November 4th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.75.

Caribou Biosciences Stock Down 1.1%

Shares of NASDAQ CRBU opened at $1.87 on Tuesday. The firm’s 50-day moving average price is $2.24 and its two-hundred day moving average price is $1.77. Caribou Biosciences has a 52-week low of $0.66 and a 52-week high of $3.54. The stock has a market capitalization of $174.79 million, a P/E ratio of -1.10 and a beta of 2.59.

Institutional Trading of Caribou Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. CWM LLC raised its holdings in Caribou Biosciences by 53.5% during the 2nd quarter. CWM LLC now owns 33,839 shares of the company’s stock worth $43,000 after buying an additional 11,798 shares during the period. R Squared Ltd purchased a new position in shares of Caribou Biosciences in the third quarter worth approximately $29,000. Vanguard Personalized Indexing Management LLC raised its holdings in shares of Caribou Biosciences by 69.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 40,813 shares of the company’s stock valued at $51,000 after acquiring an additional 16,736 shares during the period. Liberty Wealth Management LLC purchased a new stake in shares of Caribou Biosciences in the 3rd quarter valued at approximately $45,000. Finally, Next Capital Management LLC acquired a new position in Caribou Biosciences in the 2nd quarter worth approximately $25,000. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.